News & Updates

First-line tislelizumab + chemo improves OS in advanced/metastatic ESCC

23 Aug 2022 by

First-line treatment with tislelizumab + chemotherapy significantly improves overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy alone, according to an interim analysis of the RATIONALE-306* trial presented at ESMO GI 2022.

First-line tislelizumab + chemo improves OS in advanced/metastatic ESCC

23 Aug 2022

Neoadjuvant chemoradiation outperforms chemo alone for oesophageal squamous cell carcinoma

22 Aug 2022 by

Patients with oesophageal squamous cell carcinoma (ESCC) see better survival and safety outcomes after treatment with neoadjuvant chemoradiation therapy (NCRT) as compared with neoadjuvant chemotherapy (NCT) alone, according to a recent meta-analysis.

Neoadjuvant chemoradiation outperforms chemo alone for oesophageal squamous cell carcinoma

22 Aug 2022

Is bulevirtide a potential answer for chronic hep D?

20 Aug 2022 by

Bulevirtide at a dose of 2 mg or 10 mg daily induces biochemical and virological response in patients with chronic hepatitis D virus (HDV) infection, according to results of Study MYR301.

Is bulevirtide a potential answer for chronic hep D?

20 Aug 2022

Albumin, lymphocyte-to-monocyte ratio tied to tacrolimus response in ulcerative colitis

20 Aug 2022

Concentrations of albumin and the ratio between lymphocyte and monocyte counts can predict failure of tacrolimus treatment in patients with ulcerative colitis, reports a recent study.

Albumin, lymphocyte-to-monocyte ratio tied to tacrolimus response in ulcerative colitis

20 Aug 2022

Probiotics, prebiotics, synbiotics boost metabolism in NAFLD

19 Aug 2022 by

Patients with nonalcoholic fatty liver disease (NAFLD) who take probiotics, prebiotics, or synbiotics (PPS) may have better energy metabolism, according to a recent study.

Probiotics, prebiotics, synbiotics boost metabolism in NAFLD

19 Aug 2022

Upper, major GI bleeding rates higher with warfarin vs DOACs

17 Aug 2022

Treatment with warfarin appears to lead to a higher frequency of upper and major gastrointestinal (GI) bleeding as compared with direct oral anticoagulants (DOACs), a study has found.

Upper, major GI bleeding rates higher with warfarin vs DOACs

17 Aug 2022

Inflammatory bowel disease implicated in all-cause dementia risk

13 Aug 2022

Patients with both types of inflammatory bowel disease (IBD) are at risk of all-cause dementia risk, particularly frontotemporal dementia in Crohn’s disease patients, but this association may be attributed to frequent healthcare system contacts by patients with IBD detection bias, according to a study.

Inflammatory bowel disease implicated in all-cause dementia risk

13 Aug 2022

Gene-edited probiotics combat C. difficile in gut

12 Aug 2022 by

A team of scientists from Singapore has engineered probiotics that work to restore bile salt metabolism in the intestine, effectively nipping the development of Clostridioides difficile infection (CDI) in the bud.

Gene-edited probiotics combat C. difficile in gut

12 Aug 2022

High vitamin B6 status tied to better survival in stage I–III colorectal cancer

10 Aug 2022

Higher preoperative vitamin B6 status appears to improve the overall survival (OS) of patients with stage I‒III colorectal cancer (CRC), suggests a recent study.

High vitamin B6 status tied to better survival in stage I–III colorectal cancer

10 Aug 2022

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

10 Aug 2022 by

The tumour necrosis factor-alpha (TNF-α) antagonist therapies adalimumab and infliximab are more effective than vedolizumab and ustekinumab in achieving endoscopic healing (EH) at 1 year among patients with moderate-to-severe Crohn’s disease (CD), a recent study has shown.

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

10 Aug 2022

News & Updates

Filter by Specialty:

Specialty:

First-line tislelizumab + chemo improves OS in advanced/metastatic ESCC

First-line tislelizumab + chemo improves OS in advanced/metastatic ESCC

Neoadjuvant chemoradiation outperforms chemo alone for oesophageal squamous cell carcinoma

Neoadjuvant chemoradiation outperforms chemo alone for oesophageal squamous cell carcinoma

Is bulevirtide a potential answer for chronic hep D?

Is bulevirtide a potential answer for chronic hep D?

Albumin, lymphocyte-to-monocyte ratio tied to tacrolimus response in ulcerative colitis

Albumin, lymphocyte-to-monocyte ratio tied to tacrolimus response in ulcerative colitis

Probiotics, prebiotics, synbiotics boost metabolism in NAFLD

Probiotics, prebiotics, synbiotics boost metabolism in NAFLD

Upper, major GI bleeding rates higher with warfarin vs DOACs

Upper, major GI bleeding rates higher with warfarin vs DOACs

Inflammatory bowel disease implicated in all-cause dementia risk

Inflammatory bowel disease implicated in all-cause dementia risk

Gene-edited probiotics combat C. difficile in gut

Gene-edited probiotics combat C. difficile in gut

High vitamin B6 status tied to better survival in stage I–III colorectal cancer

High vitamin B6 status tied to better survival in stage I–III colorectal cancer

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD

TNF-α antagonists superior to vedolizumab, ustekinumab for endoscopic healing in CD